The synapse is typically viewed as a single compartment, which acts as a linear gain controller on incoming input. Traditional plasticity rules enable this gain control to be dynamically optimized by Hebbian activity. Whilst this view nicely captures postsynaptic function, it neglects the non-linear dynamics of presynaptic function. Here we present a two-compartment model of the synapse in which the presynaptic terminal first acts to filter presynaptic input before the postsynaptic terminal, acting as a gain controller, amplifies or depresses transmission. We argue that both compartments are equipped with distinct plasticity rules to enable them to optimally adapt synaptic transmission to the statistics of pre- and postsynaptic activity. Specifically, we focus on how presynaptic plasticity enables presynaptic filtering to be optimally tuned to only transmit information relevant for postsynaptic firing. We end by discussing the advantages of having a presynaptic filter and propose future work to explore presynaptic function and plasticity in vivo.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238589 | PMC |
http://dx.doi.org/10.1186/s13041-020-00617-1 | DOI Listing |
Clin Pharmacokinet
January 2025
Facultés de Médecine et de Pharmacie de Lyon, Univ Lyon, Université Claude Bernard Lyon 1, Lyon, France.
Background And Objective: Limited information is available on the pharmacokinetics of rifampicin (RIF) along with that of its active metabolite, 25-deacetylrifampicin (25-dRIF). This study aimed to analyse the pharmacokinetic data of RIF and 25-dRIF collected in adult patients treated for tuberculosis.
Methods: In adult patients receiving 10 mg/kg of RIF as part of a standard regimen for drug-susceptible pulmonary tuberculosis enrolled in the Opti-4TB study, plasma RIF and 25-dRIF concentrations were measured at various occasions.
MAGMA
January 2025
Imaging Physics, Fraunhofer Institute for Digital Medicine MEVIS, Max-von-Laue-Straße 2, 28359, Bremen, Germany.
Objectives: Caffeine, a known neurostimulant and adenosine antagonist, affects brain physiology by decreasing cerebral blood flow. It interacts with adenosine receptors to induce vasoconstriction, potentially disrupting brain homeostasis. However, the impact of caffeine on blood-brain barrier (BBB) permeability to water remains underexplored.
View Article and Find Full Text PDFPharmaceutics
December 2024
PerMed Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Plácido da Costa, 4200-450 Porto, Portugal.
Background: Salbutamol, a short-acting β-agonist used in asthma treatment, is available in multiple formulations, including inhalers, nebulizers, oral tablets, and intravenous, intramuscular, and subcutaneous routes. Each formulation exhibits distinct pharmacokinetic (PK) and pharmacodynamic (PD) profiles, influencing therapeutic outcomes and adverse effects. Although asthma management predominantly relies on inhaled salbutamol, understanding how these formulations interact with patient-specific characteristics could improve personalized medicine approaches, potentially uncovering the therapeutic benefits of alternative formulations for an individual patient.
View Article and Find Full Text PDFInt J Pharm
January 2025
Chair of Pharmaceutical Technology, Eberhard Karls University, Auf der Morgenstelle 8, 72074 Tuebingen, Germany. Electronic address:
Pharmaceutical 3D printing (3DP) not only offers the possibility of dose personalization but also the co-administration of multiple active pharmaceutical ingredients (APIs) in one combination tablet. In this study, Theophylline (TPH) and Prednisolone (PSL) were printed as bi-tablets, which are single tablets with two distinct separate compartments. New findings show that the combination therapy of TPH with systemic corticosteroids shows a highly synergistic effect in the treatment of pulmonary diseases.
View Article and Find Full Text PDFClin Pharmacokinet
January 2025
Laboratoire de Pharmacologie et Toxicologie, Department of Pharmacology, UR 3801, Reims University Hospital, University of Reims Champagne-Ardenne, 45 rue Cognacq Jay, 51092, Reims Cedex, France.
Background And Objective: Apixaban is increasingly being used for stroke prevention in patients with end-stage kidney disease with atrial fibrillation undergoing haemodialysis, but no pharmacostatistical model is available for dosage adjustment. This study aimed to develop a population pharmacokinetic model of apixaban in these patients to characterise its dialytic clearance and determine optimal dosing regimens and discontinuation timing before surgery.
Methods: Patients received 2.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!